India and Armenia Sign Key MoU to Enhance Medical Product Regulation
On March 11, 2025, India and Armenia strengthened their bilateral ties by signing a significant Memorandum of Understanding (MoU) aimed at enhancing cooperation in the regulation of medical products. This agreement was formalized during the visit of Armenian Foreign Minister Ararat Mirzoyan to India.
The MoU was signed between India's Central Drugs Standard ControlOrganisation (CDSCO) and Armenia's Center of Drug and Medical Technology Expertise (CDMTE), marking a crucial step towards improved regulatory frameworks for medical products in both countries. The collaboration is expected to facilitate the exchange of best practices and enhance the safety and efficacy of medical products.
During his visit, Minister Mirzoyan held discussions with Indian External Affairs Minister S. Jaishankar, focusing on various aspects of India-Armenia relations, including trade, economy, education, and cultural exchanges. Both leaders expressed optimism about expanding cooperation in digital technologies and pharmaceuticals.
The MoU reflects a commitment to deeper bilateral engagement, underscoring the historical ties and mutual interests shared by India and Armenia. As both nations explore opportunities for collaboration, this agreement is poised to have a significant impact on the pharmaceutical sectors in both countries, ensuring better access to safe medical products for their populations.
Looking for chemical products? Let suppliers reach out to you!
2026-06-18
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
AstraZeneca India Eyes ₹3,400 Crore Bengaluru Sale
-
Amazon Turns Lilly’s Weight-Loss Pill Into a Retail Logistics Play
-
Sun Pharma’s Organon Bid Would Redraw Indian Pharma M&A
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus
-
Sun Pharma’s Secret Sauce: Solve the Specific, Win the Market
-
Sun Pharma’s Winning Formula: Precision Over Expansion
-
AstraZeneca to Invest $2 Billion in New U.S. Biologics Facilities
-
EFSA Confirms Safety of Vitamin E TPGS as Food Additive New Opinion Covers Multiple Use Levels
-
Indian Pharma Urges US to Exempt Generics as 50 Percent Tariffs Loom National Security Probe Sparks Supply Fears
Recommend Reading
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
Merck to Lay Off 150 Workers at US Gardasil Plant Amid Sales Weakness
-
Iran Conflict Leaves a Long Shadow on Drug Supply
-
McKinsey Pays to Close a Purdue Liability Chapter
-
Kao Expands Halal Personal Care Product Range in Indonesia
-
BASF and Toyota Collaborate on European Automotive Refinish Project
-
September Isobutanol Prices Fluctuate and Decline
-
The Golden September Lacks Luster, Phthalic Anhydride Prices Stabilize at the Bottom in September
-
Costs Decline as September DOP Prices Fluctuate and Fall